Anti-CCR7 mAbs have shown the ability to induce tumor cell death and decrease or avoid central nervous system disease in a T-cell prolymphocytic leukaemia xenograft mice model [113], while single-chain anti-CCR7 antibodies successfully blocked the passage of T-cell acute lymphoblastic leukaemia cells through a blood–brain barrier in vitro model [165]. This evidence concerns the gene CCR7 and central nervous system disorder.